Skip to main content
Up to 53% offSee the plans

News | Stocks | Iran

Darupakhsh Pharmaceutical Raw Materials (TMVD) Books 18,401 Billion Rials of Six-Month Net Profit, Up 248% and 148% of All of Fiscal 1404

Sahmino Newsroom | 19 November 2026 | 20 hours ago

TMVDup0.3%70,880rials18 November

In its audited standalone income statement for the six months to 31 Shahrivar 1405 (22 September 2026), filed on Codal on 19 November 2026, Darupakhsh Pharmaceutical Raw Materials (TMVD) reported operating revenue of 41,090 billion rials, up 174% from 15,020 billion rials in the same period a year earlier (restated).

Gross profit grew 259% to 25,265 billion rials, and the gross margin rose from 46.9% to 61.5%. Operating profit came to 24,163 billion rials (up 257%) and net profit to 18,401 billion rials, against 5,294 billion rials a year earlier. That net profit equals 148% of the full-year profit for fiscal 1404 (12,454 billion rials).

Current-year income tax was 4,917 billion rials (1,069 billion rials a year earlier) and finance costs 846 billion rials. Share capital is 2,800 billion rials.

Reference:CodalThe original report

Sahmino context

What the prices have done since this story was published, and what Sahmino wrote around it

Sahmino's reading

TMVD closed on Wednesday 18 November at 70,430 rials, 4.6% above its 24 October close of 67,350 rials, and touched its 52-week high of 71,890 rials in that same session. The exchange P/E on that close is 7.81 against 11.14 for its sector, struck on a trailing EPS of 9,015 rials that predates this filing (nightly reading of 17 November).

More from this market